RIO DE JANEIRO, BRAZIL - The pharmaceutical manufacturer said on Thursday, July 1, that its vaccine led to the production of antibodies that lasted at least 8 months against all variants, including the Delta, first detected in India and which has spread worldwide, raising concern in many countries.
The Indian variant is expected to become the dominant strain in the United States in coming weeks, according to the Centers for Disease Control and Prevention (CDCs).
J&J's vaccine reputedly offers less protection than Pfizer's and Moderna's messenger RNA vaccines, and experts are now discussing whether booster doses . . .